Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4360 in Adult Participants With Advanced Solid Tumours
NCT06921928Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of AZD4360 in gastric cancer (GC), gastroesophageal junction cancer, biliary tract cancer (BTC) and 1 more, sponsored by AstraZeneca. Primary endpoints: Dose-Limiting Toxicity up to 2 years and Adverse Events up to 2 years. Started Apr 2025; status: active, not recruiting.
02
Drugs
AZD4360
03
Conditions
gastric cancer (GC)gastroesophageal junction cancerbiliary tract cancer (BTC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06921928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06921928.